Needle-free injection market set for rapid growth through 2030

The medical needle-free injection market is projected to climb from $16.13 billion in 2025 to $29.21 billion by 2030, according to a new report from The Business Research Company. Rising diabetes cases, broader vaccination efforts and demand for less invasive drug delivery are fueling the shift.

Why it matters: - Needle-free injection technology could make routine drug delivery less painful and less intimidating for patients who need frequent treatment. - The market’s growth points to wider demand for self-administered therapies, better vaccination access and patient-friendly devices.

What happened: - The Business Research Company published a 2026 report on the global medical needle-free injection market. - The market is projected to rise from $16.13 billion in 2025 to $18.19 billion in 2026. - The report forecasts the market will reach $29.21 billion by 2030. - The forecast implies a 12.7% CAGR from 2025 to 2026 and a 12.6% CAGR through 2030. - The report includes a free sample and the full market report.

The details: - Needle-free injection devices deliver medication or vaccines through the skin using high-pressure technology. - The devices create a fine, high-velocity liquid jet that penetrates the skin without a traditional needle. - The technology is designed to reduce fear and discomfort during injections. - The report cites chronic illness prevalence, expanded vaccination programs, needle-stick injury concerns, growth in outpatient care and adoption of non-invasive treatments as historic growth drivers. - Future growth drivers include investment in drug-delivery technology, more self-administered therapies, biologics and vaccine pipelines, patient-friendly devices and microfluidic injection systems. - The report highlights wider adoption of painless delivery systems, demand for needle-free vaccination, electronically controlled injection devices, home-based self-administration and a focus on comfort and adherence as key trends. - Rising diabetes cases remain a major market driver because needle-free injections can support insulin delivery and other frequent treatments. - The National Health Service reported that 3,615,330 people registered with general practitioners in the UK were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - In 2025, North America held the largest share of the global market. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies, future trends and updated graphics and tables.

Between the lines: - The report suggests the market is moving from a niche convenience product to a broader delivery platform for chronic disease care and preventive medicine. - Growth in home-based administration and electronically controlled devices points to more decentralized care models. - Diabetes and pre-diabetes trends expand the addressable base for painless, repeat-use delivery tools.

What's next: - Adoption should continue rising as healthcare systems look for less invasive delivery methods and patients seek easier self-administration. - Asia-Pacific’s growth could narrow the gap with North America as chronic disease rates and vaccination programs expand. - Ongoing innovation in microfluidics and electronic control may shape the next wave of product development.

The bottom line: - Needle-free injection is moving into a higher-growth phase as patient comfort, chronic disease management and drug-delivery innovation converge.